Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled study.

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled study.
Authors: Hamer MJ; Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA; Department of Emergency Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA., McCarty JM; Stanford University School of Medicine, Stanford, CA, USA., Pierson BC; Division of Medicine, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, USA., Regules JA; Division of Medicine, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, USA; Uniformed Services University (USU) F Edward Hebert School of Medicine, Bethesda, MD, USA., Mendy J; Bavarian Nordic, San Diego, CA, USA., Sanborn AD; Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA., Gardner CL; Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, USA., Haller JM; Division of Medicine, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, USA., Gregory MK; Division of Medicine, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, USA., Liggett DL; Division of Medicine, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, USA., Glass PJ; Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, USA., Ghosh N; Emergent BioSolutions, Gaithersburg, MD, USA., Royalty Tredo S; Emergent BioSolutions, Gaithersburg, MD, USA., Warfield KL; Emergent BioSolutions, Gaithersburg, MD, USA., Burke CW; Virology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, USA., Lee C; Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA., Saunders D; Division of Medicine, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, USA; Uniformed Services University (USU) F Edward Hebert School of Medicine, Bethesda, MD, USA., Bedell L; Bavarian Nordic, San Diego, CA, USA., Richardson JS; Bavarian Nordic Canada, Toronto, ON, Canada. Electronic address: JARI@bavarian-nordic.com.
Source: The Lancet. Microbe [Lancet Microbe] 2025 Apr; Vol. 6 (4), pp. 101000. Date of Electronic Publication: 2025 Feb 12.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-5247
DOI:10.1016/j.lanmic.2024.101000